Literature DB >> 19959578

Candida albicans biofilm formation in a new in vivo rat model.

Markéta Řičicová1,2, Soňa Kucharíková1,2,3, Hélène Tournu1,2, Jelle Hendrix4, Helena Bujdáková3, Johan Van Eldere5, Katrien Lagrou5, Patrick Van Dijck1,2.   

Abstract

Device-associated microbial growth, including Candida biofilms, represents more than half of all human microbial infections and, despite a relatively small risk of implant-associated diseases, this type of infection usually leads to high morbidity, increased health-care costs and prolonged antimicrobial therapy. Animal models are needed to elucidate the complex host-pathogen interactions that occur during the development of attached and structured biofilm populations. We describe here a new in vivo model to study Candida biofilm, based on the avascular implantation of small catheters in rats. Polyurethane biomaterials challenged with Candida cells were placed underneath the skin of immunosuppressed animals following only minor surgery. The model allowed the study of up to ten biofilms at once, and the recovery of mature biofilms from 2 days after implantation. The adhering inoculum was adjusted to the standard threshold of positive diagnosis of fungal infection in materials recovered from patients. Wild-type biofilms were mainly formed of hyphal cells, and they were unevenly distributed across the catheter length as observed in infected materials in clinical cases. The hyphal multilayered structure of the biofilms of wild-type strains was observed by confocal microscopy and compared to the monolayer of yeast or hyphal cells of two well-known biofilm-deficient strains, efg1Delta/efg1 Delta cph1Delta/cph1Delta and bcr1Delta /bcr1Delta, respectively. The subcutaneous Candida biofilm model relies on the use of implanted catheters with accessible, fast and minor surgery to the animals. This model can be used to characterize the ability of antimicrobial agents to eliminate biofilms, and to evaluate the prophylactic effect of antifungal drugs and biomaterial coatings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959578     DOI: 10.1099/mic.0.033530-0

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  43 in total

Review 1.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

2.  Genetic control of Candida albicans biofilm development.

Authors:  Jonathan S Finkel; Aaron P Mitchell
Journal:  Nat Rev Microbiol       Date:  2010-12-29       Impact factor: 60.633

3.  Plant-derived decapeptide OSIP108 interferes with Candida albicans biofilm formation without affecting cell viability.

Authors:  Nicolas Delattin; Katrijn De Brucker; David J Craik; Olivier Cheneval; Mirjam Fröhlich; Matija Veber; Lenart Girandon; Talya R Davis; Anne E Weeks; Carol A Kumamoto; Paul Cos; Tom Coenye; Barbara De Coninck; Bruno P A Cammue; Karin Thevissen
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  Synergistic Antifungal Effect of Amphotericin B-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles and Ultrasound against Candida albicans Biofilms.

Authors:  Min Yang; Kaiyue Du; Yuru Hou; Shuang Xie; Yu Dong; Dairong Li; Yonghong Du
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 5.  Antifungal therapy with an emphasis on biofilms.

Authors:  Christopher G Pierce; Anand Srinivasan; Priya Uppuluri; Anand K Ramasubramanian; José L López-Ribot
Journal:  Curr Opin Pharmacol       Date:  2013-09-04       Impact factor: 5.547

Review 6.  Plasticity of Candida albicans Biofilms.

Authors:  David R Soll; Karla J Daniels
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-01       Impact factor: 11.056

7.  Assessment and Optimizations of Candida albicans In Vitro Biofilm Assays.

Authors:  Matthew B Lohse; Megha Gulati; Ashley Valle Arevalo; Adam Fishburn; Alexander D Johnson; Clarissa J Nobile
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

8.  Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs.

Authors:  Jeniel E Nett; David R Andes
Journal:  Microbiol Spectr       Date:  2015-06

9.  Real-time PCR expression profiling of genes encoding potential virulence factors in Candida albicans biofilms: identification of model-dependent and -independent gene expression.

Authors:  Heleen Nailis; Sona Kucharíková; Markéta Ricicová; Patrick Van Dijck; Dieter Deforce; Hans Nelis; Tom Coenye
Journal:  BMC Microbiol       Date:  2010-04-16       Impact factor: 3.605

10.  DL-2-hydroxyisocaproic acid attenuates inflammatory responses in a murine Candida albicans biofilm model.

Authors:  M T Nieminen; M Hernandez; L Novak-Frazer; H Kuula; G Ramage; P Bowyer; P Warn; T Sorsa; R Rautemaa
Journal:  Clin Vaccine Immunol       Date:  2014-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.